Products Paritaprevir was approved in many countries in 2014 in film-coated tablet form (Viekirax, combination drug). Effects Paritaprevir has antiviral properties against HCV. The effects are due to binding to the NS3/4A protease complex. HCV NS3 serine protease is an enzyme involved in viral replication. To increase availability and allow once-daily administration, paritaprevir is combined … Paritaprevir
Background It is estimated that more than 180 million people worldwide are chronically infected with the hepatitis C virus. Potential severe complications of hepatitis include cirrhosis, liver carcinoma, and liver failure. Of the various genotypes of the virus, genotype 1 in particular responds poorly to current treatment (50%). Standard drugs used include subcutaneous peginterferon alfa … Boceprevir
Products Asunaprevir is not currently registered in many countries. It has been approved in Japan since 2014 (Sunvepra, Bristol-Myers Squibb) and is used in combination with daclatasvir (Daklinza) as an interferon and ribavirin-free treatment. Structure and properties Asunaprevir (C35H46ClN5O9S, Mr = 748.3 g/mol) Effects Asunaprevir has antiviral properties. The effects are due to selective and … Asunaprevir
Products Telaprevir is commercially available in the form of film-coated tablets (Incivo). It was approved in many countries in 2011. Structure and properties Telaprevir (C36H53N7O6, Mr = 679.8 g/mol) is a peptidomimetic and a ketoamide. It exists as a white crystalline powder that is sparingly soluble in water. Telaprevir is converted in the body to … Telaprevir
Products Voxilaprevir is commercially available as film-coated tablets in fixed combination with sofosbuvir and velpatasvir (Vosevi). It was approved in the United States, many countries, and the EU in 2017. Structure and properties Voxilaprevir (C40H52F4N6O9S, Mr = 868.9 g/mol) Effects Voxilaprevir has antiviral properties. The effects are due to noncovalent and reversible inhibition of the … Voxilaprevir
Products Simeprevir was approved in capsule form in the United States in 2013, in the EU in 2014, and in many countries in 2015 (Olysio). Structure and properties Simeprevir (C38H47N5O7S2, Mr = 749.9 g/mol) is present in the drug product as simeprevir sodium. The macrocyclic molecule contains a sulfonamide moiety, which may cause adverse effects … Simeprevir
